Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges

Area of Science:

• Biochemistry
• Mycology
• Pharmacology

Background:

• CYP51 is a vital monooxygenase in the sterol synthesis pathway, essential for fungal membrane integrity.
• Inhibition of fungal CYP51 disrupts ergosterol synthesis, leading to fungal cell apoptosis and making it a key antifungal target.
• Current CYP51 inhibitors face challenges including resistance, hepatotoxicity, and drug interactions.

Purpose of the Study:

• To review the structural features and biological roles of CYP51.
• To analyze the structure-activity relationships (SAR) of small-molecule CYP51 inhibitors.
• To discuss novel strategies and therapeutic potential for developing improved antifungal drugs targeting CYP51.

Main Methods:

• Literature review and analysis of existing data on CYP51 inhibitors.
• Examination of structure-activity relationships (SAR) for various chemical classes of CYP51 inhibitors.
• Discussion of recent advancements in novel therapeutic strategies targeting CYP51.

Main Results:

• CYP51's critical role in fungal ergosterol synthesis is confirmed as a viable antifungal target.
• Analysis reveals diverse SAR for small-molecule CYP51 inhibitors, highlighting potential for optimization.
• Emerging strategies aim to enhance selectivity and overcome resistance associated with current inhibitors.

Conclusions:

• CYP51 remains a crucial target for antifungal drug development.
• Further research into SAR and novel strategies is needed to create effective, safe, and resistance-overcoming CYP51 inhibitors.
• Optimized CYP51 inhibitors hold significant promise for treating invasive fungal infections.